Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-ValvePlus products from the New Zealand Medicines and Medical Devices Safety Authority, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - The Ken-Valve and LuX-ValvePlus systems have recently obtained registration approval in New Zealand [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages and ongoing clinical trials [1] - Continuous promotion of the therapies has contributed to the positive reception of the products [1] Group 3: Strategic Goals - The company aims to expedite the global commercialization process of its product lineup to achieve its long-term strategic objectives [1]
健世科技-B：Ken-Valve和LuX-Valve Plus获得新西兰注册批准